Published in J Infect Dis on February 01, 2010
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Models for the study of Clostridium difficile infection. Gut Microbes (2012) 1.16
A pig model of the human gastrointestinal tract. Gut Microbes (2013) 1.15
The Clostridium difficile cell wall protein CwpV is antigenically variable between strains, but exhibits conserved aggregation-promoting function. PLoS Pathog (2011) 1.11
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Both, toxin A and toxin B, are important in Clostridium difficile infection. Gut Microbes (2011) 1.06
A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model. Clin Vaccine Immunol (2013) 1.03
A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis (2014) 1.02
Clostridium difficile in the ICU: the struggle continues. Chest (2011) 1.01
Clostridium difficile infection. Nat Rev Dis Prim (2016) 0.99
Muricholic acids inhibit Clostridium difficile spore germination and growth. PLoS One (2013) 0.98
Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection. Gut Microbes (2013) 0.94
The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge. Zoonoses Public Health (2010) 0.93
Clostridium difficile infection: molecular pathogenesis and novel therapeutics. Expert Rev Anti Infect Ther (2014) 0.92
Identification of toxemia in patients with Clostridium difficile infection. PLoS One (2015) 0.84
Beneficial effect of oral tigecycline treatment on Clostridium difficile infection in gnotobiotic piglets. Antimicrob Agents Chemother (2014) 0.82
Temporal differential proteomes of Clostridium difficile in the pig ileal-ligated loop model. PLoS One (2012) 0.81
Systemically administered IgG anti-toxin antibodies protect the colonic mucosa during infection with Clostridium difficile in the piglet model. PLoS One (2014) 0.79
MBX-500 is effective for treatment of Clostridium difficile infection in gnotobiotic piglets. Antimicrob Agents Chemother (2013) 0.79
The non-toxigenic Clostridium difficile CD37 protects mice against infection with a BI/NAP1/027 type of C. difficile strain. Anaerobe (2015) 0.79
Prevalence and genotypic characteristics of Clostridium difficile in a closed and integrated human and swine population. Appl Environ Microbiol (2011) 0.78
A Detrimental Role of Immunosuppressive Drug, Dexamethasone, During Clostridium difficile Infection in Association with a Gastrointestinal Microbial Shift. J Microbiol Biotechnol (2016) 0.78
Retargeting Clostridium difficile Toxin B to Neuronal Cells as a Potential Vehicle for Cytosolic Delivery of Therapeutic Biomolecules to Treat Botulism. J Toxicol (2011) 0.78
Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection. J Infect Dis (2014) 0.77
A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection. Clin Vaccine Immunol (2016) 0.75
Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B. Infect Immun (2015) 0.75
The roles of toxin A and toxin B in Clostridium difficile infection: insights from the gnotobiotic piglet model. Gut Microbes (2013) 0.75
Collateral damage during antibiotic treatment of C. difficile infection in the aged host: insights into why recurrent disease happens. Gut Microbes (2017) 0.75
The therapeutic efficacy of azithromycin and nitazoxanide in the acute pig model of Cryptosporidium hominis. PLoS One (2017) 0.75
Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis (2001) 6.92
Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun (1985) 5.44
Fatal pseudomembranous colitis associated with a variant clostridium difficile strain not detected by toxin A immunoassay. Ann Intern Med (2001) 2.72
The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect Immun (1995) 2.69
Colitis due to Clostridium difficile toxins: underdiagnosed, highly virulent, and nosocomial. Proc (Bayl Univ Med Cent) (2006) 2.26
Clostridium difficile: an important pathogen of food animals. Anaerobe (2005) 2.01
Clostridium difficile colitis associated with chronic renal failure. Nephrol Dial Transplant (1998) 1.94
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89
Use of cycloserine-cefoxitin-fructose agar and L-proline-aminopeptidase (PRO Discs) in the rapid identification of Clostridium difficile. J Clin Microbiol (1997) 1.85
Clostridial enteric infections in pigs. J Vet Diagn Invest (2005) 1.83
The challenges posed by reemerging Clostridium difficile infection. Clin Infect Dis (2007) 1.66
Clostridium difficile-associated diarrhoea. Intern Med J (2007) 1.54
Ascites associated with antibiotic-associated pseudomembranous colitis. South Med J (1996) 1.51
An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods (2009) 1.34
Clostridium difficile colitis causing toxic megacolon, severe sepsis and multiple organ dysfunction syndrome. Intensive Care Med (2003) 1.28
The comparative pathology of Clostridium difficile-associated disease. Vet Pathol (2006) 1.26
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
Clostridium difficile and acute respiratory distress syndrome. Heart Lung (2004) 1.11
A common polymorphism in the interleukin 8 gene promoter is associated with Clostridium difficile diarrhea. Am J Gastroenterol (2006) 1.06
Clostridium difficile toxins A and B directly stimulate human mast cells. Infect Immun (2007) 0.97
Liver abscess caused by Clostridium difficile. Scand J Infect Dis (2001) 0.95
Severe pseudomembranous enterocolitis in a child: case report and literature review. Pediatr Infect Dis J (1989) 0.94
Pseudomembranous colitis: report of a severe case with unusual clinical signs in a young nurse. Dis Colon Rectum (2000) 0.93
Nosocomial empyema caused by Clostridium difficile. J Clin Pathol (1996) 0.93
A rare and unsuspected complication of Clostridium difficile infection. Intensive Care Med (2007) 0.91
Is cardiorespiratory failure induced by bacterial toxins the cause of sudden infant death syndrome? Studies with an animal model (the rabbit). Toxicon (1995) 0.91
Toxigenic C. difficile induced inflammatory marker expression by human intestinal epithelial cells is asymmetrical. Life Sci (2005) 0.86
A case of pseudomembranous colitis presenting with massive ascites. Eur J Intern Med (2007) 0.86
Complete genome sequence of the apicomplexan, Cryptosporidium parvum. Science (2004) 5.64
The genome of Cryptosporidium hominis. Nature (2004) 3.93
Systemic dissemination of Clostridium difficile toxins A and B is associated with severe, fatal disease in animal models. J Infect Dis (2011) 1.98
Cryptosporidiosis and microsporidiosis in ugandan children with persistent diarrhea with and without concurrent infection with the human immunodeficiency virus. Am J Trop Med Hyg (2005) 1.90
Expression of recombinant Clostridium difficile toxin A and B in Bacillus megaterium. BMC Microbiol (2008) 1.89
Self-regulation of Candida albicans population size during GI colonization. PLoS Pathog (2007) 1.85
Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology (2010) 1.83
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
Prevalence of Enterocytozoon bieneusi in swine: an 18-month survey at a slaughterhouse in Massachusetts. Appl Environ Microbiol (2002) 1.78
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Genomic survey of the non-cultivatable opportunistic human pathogen, Enterocytozoon bieneusi. PLoS Pathog (2009) 1.73
Cryptosporidium parvum in children with diarrhea in Mulago Hospital, Kampala, Uganda. Am J Trop Med Hyg (2003) 1.64
Respiratory cryptosporidiosis in HIV-seronegative children in Uganda: potential for respiratory transmission. Clin Infect Dis (2010) 1.56
Enterocytozoon bieneusi among children with diarrhea attending Mulago Hospital in Uganda. Am J Trop Med Hyg (2002) 1.50
Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun (2002) 1.49
Cryptosporidiosis in children in Sub-Saharan Africa: a lingering challenge. Clin Infect Dis (2008) 1.46
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun (2005) 1.38
Mouse relapse model of Clostridium difficile infection. Infect Immun (2011) 1.36
Cryptosporidium hominis: experimental challenge of healthy adults. Am J Trop Med Hyg (2006) 1.35
An ultrasensitive rapid immunocytotoxicity assay for detecting Clostridium difficile toxins. J Microbiol Methods (2009) 1.34
The reduced genome of the parasitic microsporidian Enterocytozoon bieneusi lacks genes for core carbon metabolism. Genome Biol Evol (2010) 1.30
The shikimate pathway and its branches in apicomplexan parasites. J Infect Dis (2002) 1.25
Antibody against TcdB, but not TcdA, prevents development of gastrointestinal and systemic Clostridium difficile disease. J Infect Dis (2012) 1.25
A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One (2012) 1.24
Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun (2002) 1.23
Infectivity of a Cryptosporidium parvum isolate of cervine origin for healthy adults and interferon-gamma knockout mice. J Infect Dis (2002) 1.22
A chimeric toxin vaccine protects against primary and recurrent Clostridium difficile infection. Infect Immun (2012) 1.22
Identification of genotypically mixed Cryptosporidium parvum populations in humans and calves. Mol Biochem Parasitol (2003) 1.21
Antibody-enhanced, Fc gamma receptor-mediated endocytosis of Clostridium difficile toxin A. Infect Immun (2009) 1.21
Host S-nitrosylation inhibits clostridial small molecule-activated glucosylating toxins. Nat Med (2011) 1.19
Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect Immun (2008) 1.19
Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry (2008) 1.17
Patterns of genome evolution among the microsporidian parasites Encephalitozoon cuniculi, Antonospora locustae and Enterocytozoon bieneusi. PLoS One (2007) 1.16
A pig model of the human gastrointestinal tract. Gut Microbes (2013) 1.15
Inferences about the global population structures of Cryptosporidium parvum and Cryptosporidium hominis. Appl Environ Microbiol (2008) 1.15
Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun (2003) 1.12
Experimental evidence for genetic recombination in the opportunistic pathogen Cryptosporidium parvum. Mol Biochem Parasitol (2002) 1.09
Increased adherence and actin pedestal formation by dam-deficient enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol (2007) 1.09
The enterotoxicity of Clostridium difficile toxins. Toxins (Basel) (2010) 1.07
Characterization of RAP, a quorum sensing activator of Staphylococcus aureus. FEMS Microbiol Lett (2003) 1.06
A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun (2013) 1.06
EspFU, a type III-translocated effector of actin assembly, fosters epithelial association and late-stage intestinal colonization by E. coli O157:H7. Cell Microbiol (2007) 1.06
Detection and genotyping of oocysts of Cryptosporidium parvum by real-time PCR and melting curve analysis. J Clin Microbiol (2002) 1.05
Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother (2003) 1.05
Characterization of Cryptosporidium meleagridis of human origin passaged through different host species. Infect Immun (2003) 1.02
Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun (2009) 1.02
Granzyme B binds to target cells mostly by charge and must be added at the same time as perforin to trigger apoptosis. J Immunol (2005) 1.00
Tumor-derived, chaperone-rich cell lysate activates dendritic cells and elicits potent antitumor immunity. Blood (2003) 0.99
Essential role of the glucosyltransferase activity in Clostridium difficile toxin-induced secretion of TNF-alpha by macrophages. Microb Pathog (2009) 0.99
Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis (2009) 0.98
A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol (2005) 0.98
Development of a Bacillus subtilis-based rotavirus vaccine. Clin Vaccine Immunol (2010) 0.98
Production and characterization of monoclonal antibodies against Enterocytozoon bieneusi purified from rhesus macaques. Infect Immun (2005) 0.97
Purification of Enterocytozoon bieneusi from stools and production of specific antibodies. J Clin Microbiol (2005) 0.97
Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target. Int J Parasitol (2004) 0.95
The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteins. Proteomics (2009) 0.94
A segment of 97 amino acids within the translocation domain of Clostridium difficile toxin B is essential for toxicity. PLoS One (2013) 0.93
Rapid displacement of Cryptosporidium parvum type 1 by type 2 in mixed infections in piglets. Infect Immun (2003) 0.92
Subtype analysis of Cryptosporidium isolates from children in Uganda. J Parasitol (2006) 0.91
Allele- and tir-independent functions of intimin in diverse animal infection models. Front Microbiol (2012) 0.91
Microsporidiosis and malnutrition in children with persistent diarrhea, Uganda. Emerg Infect Dis (2009) 0.91
Comparison of two label-free global quantitation methods, APEX and 2D gel electrophoresis, applied to the Shigella dysenteriae proteome. Proteome Sci (2009) 0.91
Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2. Infect Immun (2010) 0.91
Quantitative tracking of Cryptosporidium infection in cell culture with CFSE. J Parasitol (2006) 0.91
Bacillus subtilis: a temperature resistant and needle free delivery system of immunogens. Hum Vaccin Immunother (2012) 0.90
Tegumental phosphodiesterase SmNPP-5 is a virulence factor for schistosomes. Infect Immun (2011) 0.90
Cytotoxicity of Clostridium difficile toxin B does not require cysteine protease-mediated autocleavage and release of the glucosyltransferase domain into the host cell cytosol. Pathog Dis (2013) 0.90
Enhanced Actin Pedestal Formation by Enterohemorrhagic Escherichia coli O157:H7 Adapted to the Mammalian Host. Front Microbiol (2011) 0.90
Monoclonal antibodies against Enterocytozoon bieneusi of human origin. Clin Diagn Lab Immunol (2005) 0.90
Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine (2010) 0.89
Infection with Cryptosporidium hominis provides incomplete protection of the host against Cryptosporidium parvum. J Infect Dis (2012) 0.89
Cryptosporidium meleagridis: infectivity in healthy adult volunteers. Am J Trop Med Hyg (2011) 0.89
Serial propagation of the microsporidian Enterocytozoon bieneusi of human origin in immunocompromised rodents. Infect Immun (2006) 0.89
Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile. Hum Vaccin Immunother (2013) 0.87
Ischemic postconditioning does not attenuate ischemia-reperfusion injury of rabbit small intestine. Vet Surg (2010) 0.86
In vivo versus in vitro protein abundance analysis of Shigella dysenteriae type 1 reveals changes in the expression of proteins involved in virulence, stress and energy metabolism. BMC Microbiol (2011) 0.86
A piglet model of acute gastroenteritis induced by Shigella dysenteriae Type 1. J Infect Dis (2010) 0.86
Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine (2011) 0.86
Improved healing of large segmental defects in the rat femur by reverse dynamization in the presence of bone morphogenetic protein-2. J Bone Joint Surg Am (2012) 0.86
Bile acids enhance invasiveness of Cryptosporidium spp. into cultured cells. Infect Immun (2006) 0.86
Multivariate modeling identifies neutrophil- and Th17-related factors as differential serum biomarkers of chronic murine colitis. PLoS One (2010) 0.85
Analysis of the beta-tubulin genes from Enterocytozoon bieneusi isolates from a human and rhesus macaque. J Eukaryot Microbiol (2007) 0.85
MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile. Antimicrob Agents Chemother (2012) 0.85
Sensitivity and specificity of a monoclonal antibody-based fluorescence assay for detecting Enterocytozoon bieneusi spores in feces of simian immunodeficiency virus-infected macaques. Clin Diagn Lab Immunol (2005) 0.84
Characterizing the Escherichia coli O157:H7 proteome including protein associations with higher order assemblies. PLoS One (2011) 0.84
Immune-based treatment and prevention of Clostridium difficile infection. Hum Vaccin Immunother (2014) 0.84
In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2. BMC Immunol (2010) 0.84
Down-regulation of interleukin-16 in human mast cells HMC-1 by Clostridium difficile toxins A and B. Naunyn Schmiedebergs Arch Pharmacol (2011) 0.84
Failure to propagate Cryptosporidium spp. in cell-free culture. J Parasitol (2006) 0.84
Sublingual immunization with an engineered Bacillus subtilis strain expressing tetanus toxin fragment C induces systemic and mucosal immune responses in piglets. Microbes Infect (2011) 0.83